ASCO Conference Coverage
Featured Articles
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
Read Article
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
Read Article
Latest Articles
June 25, 2019
June 14, 2019
June 12, 2019
June 12, 2019
June 11, 2019
June 06, 2019
June 06, 2019
June 06, 2019
View More
News Commentary
Editor Image
18 May, 2020 | by H. Jack West, MD
Good to see another contender for the molecularly defined population that has...
View Comment
Editor Image
14 May, 2020 | by Tomasz M. Beer, MD
We expect to see overall survival results from several agents in non-metastatic...
View Comment
View More
OBR Blog
Today, four plenary sessions dropped at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting featured... Read more
June 02, 2019
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019

OBR Tweets

May 26
H. Jack West, MD: Another option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib… https://t.co/k9fEkGefkq

May 26
H. Jack West, MD: Elderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse eff… https://t.co/qvJRVE5FyX

May 22
A recent FDA workshop delved into liquid biopsy screening approaches as they are increasingly being applied, partic… https://t.co/ZC83sOvoO2

May 21
H. Jack West, MD: While it's always nice to have another option, it's hard for me to see how atezolizumab provides… https://t.co/TUgQMgLwcA

May 21
Tomasz M. Beer, MD: PAPR inhibitor approval means that we will need to genotype all advanced prostate cancer patien… https://t.co/V0TnoRIDfR

May 20
At the #aacr2020 Virtual Meeting I, there was pivotal data from immunotherapy triplet trials in breast cancer, mela… https://t.co/eJ1m97OA6G

May 20
The emergence of #COVID-19 has transformed the care of cancer patients and upended the way practices do business. D… https://t.co/yLcc5dTpjn

May 19
At @oncologyCOA's first virtual conference, presenters discussed modernizing the clinical trial process, the comple… https://t.co/VIBVh1b8bA

May 19
Join us Tonight, May 19th 7:30 ET for a webinar discussing the unique management of advanced hepatocellular carcino… https://t.co/lgdd4xzlDb

May 19
H. Jack West, MD: I imagine that the nivolumab/ipilumumab combination will have some appeal to patients or physicia… https://t.co/faXlyOvMeC